

Media Contact:
Drew Avril
coActive Public Relations
718-871-7117
davril@coactivepr.com

SOLX Initiates Glaucoma Clinical Trials for the DeepLight® Gold Micro-Shunt

–First Glaucoma Device to Lower Intraocular Pressure without a Bleb –

BOSTON, October 18, 2005 – SOLX, Inc. today announced Investigational Device Exemption (IDE) approval from the U.S. Food & Drug Administration (FDA) to begin studies of the DeepLight Gold Micro-Shunt (GMS) implant for glaucoma. This randomized, multi-center study will evaluate safety and efficacy of the GMS for lowering intraocular pressure (IOP) in primary open-angle glaucoma.

“This is the first 24-karat gold implant that uses the eye’s natural pressure differential to reduce IOP without a bleb,” said Gabriel Simon, MD, PhD, Director of Ophthalmic Research at the Boston University Photonics Center and Research Professor of Biomedical Engineering at Boston University. “The GMS has the potential to replace all tube-based shunts and eliminate trabeculectomy procedures.”

Multi-center studies of 70 eyes with up to two years follow-up conducted in Spain and Israel demonstrated excellent clinical results. This IDE approval follows CE approval by an authorized European authority’s notified body Intertek/Amtac.

The randomized study will take place at up to ten centers worldwide on open-angle glaucoma patients that have failed maximum medical therapy and at least one surgical intervention.

About the DeepLight® Glaucoma Treatment System

The DeepLight Glaucoma Treatment System includes the DeepLight Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt (GMS), which can be used separately or together to provide patients with multiple options for maximum IOP reduction. The 790 Titanium Sapphire solid-state laser was CE approved by authorized European authority’s notified body in December 2004 and has been shown to provide deeper tissue penetration than other lasers currently used in trabeculoplasty, to a depth of approximately 200 microns, without causing thermal damage to the trabecular meshwork.

- more -

The GMS is a 24-karat gold ultra-thin implant that is approximately one-third the thickness of a human hair. This device is not a tube, but a flat plate designed for implantation through a single micro-incision. It contains numerous micro-tubular channels that bridge the anterior chamber and suprachoroidal space, maximizing uveoscleral outflow to reduce IOP. The GMS rests permanently in the suprachoroidal space and cannot be felt by the patient. It is bio-compatible, physically inert and has been shown to eliminate the formation of scar tissue.

About SOLX

Based at the Boston University Photonics Center in Boston, Massachusetts, SOLX is a privately held company developing new approaches to glaucoma treatment. SOLX's DeepLight Glaucoma Treatment System is being developed to provide physicians with new tools to reduce intraocular pressure in glaucoma sufferers through its DeepLight 790 Titanium Sapphire Laser and DeepLight Gold Micro-Shunt (GMS). More information can be found online at www.SOLX.com.

About The Photonics Center at Boston University

The Photonics Center at Boston University identifies and develops technologies based on the practical application of light. The Photonics Center hosts a Business Accelerator program that enables emerging photonics technology companies to grow from idea to commercialization with greater speed and success. The Photonics Center provides an entrepreneurial environment that includes 20 laboratories, workspace for up to 20 start-up companies, and access to a range of equipment worth in excess of \$40 million. For more information, please visit www.thephotonicscenter.com.